XTL Biopharmaceuticals Extraordinary General Meetings Postponed Until October 10, 2008

VALLEY COTTAGE, N.Y., Oct. 2 XTLBiopharmaceuticals Ltd. (Nasdaq: XTLB; TASE: XTL) today announced that itsExtraordinary General Meetings ("EGMs") were postponed until October 10, 2008in accordance with its articles of association due to the absence of a quorum.The postponed EGMs will take place at the offices of Kantor & Co. Law Offices,14 Abba Hillel Silver Road, Oz House, 12th Floor, Ramat Gan, Israel at 3:00p.m. Israel time, and 5:30 p.m. Israel time, respectively, on October 10,2008.

Any proxy votes received at any time up to 48 hours prior to the postponedEGMs will be included in the total votes counted for the EGMs. Thoseshareholders who have a valid "proof of ownership" in Israel or a letter ofrepresentation from Computershare, the Company's United Kingdom registrars,and attend the meeting in person will also be permitted to vote.

ABOUT XTL BIOPHARMACEUTICALS LTD.

XTL Biopharmaceuticals Ltd. ("XTL") is engaged in the development oftherapeutics for the treatment of diabetic neuropathic pain and HCV. XTL isdeveloping Bicifadine, a serotonin and norepinephrine reuptake inhibitor, forthe treatment of diabetic neuropathic pain, which is currently in a Phase 2bstudy. XTL has out-licensed its novel pre-clinical HCV small moleculeinhibitor program. XTL also has an active in-licensing and acquisition programdesigned to identify and acquire additional drug candidates. XTL is publiclytraded on the NASDAQ and Tel-Aviv Stock Exchanges (NASDAQ: XTLB; TASE: XTL).

SOURCE XTL Biopharmaceuticals Ltd.

Latest Press Release on General News

Precision oncology company Flindr Therapeutics announces €20 million Series A financing to advance first-in-class small molecule inhibitors

V-Bio Ventures leads international syndicate which includes Johnson & Johnson Innovation – JJDC, Inc., QBIC Fund, Flanders Future Tech Fund, Curie Capital as well as seed investor...

Rett Syndrome Research Trust Partners with Vivalink to Shift Symptom Assessment Paradigms in Rett Syndrome

Vivalink's remote patient monitoring solutions accelerate research into rare neurological disorder CAMPBELL, Calif. , April 23, 2024 /PRNewswire/ -- Vivalink , a leading pro...

World IBS Day - April 19th: Raising Awareness for Everyone with IBS

Debunking myths about Irritable Bowel Syndrome TORONTO , April 18, 2024 /PRNewswire/ -- IBS is a chronic gastrointestinal disorder with symptoms like abdominal pain, bloating,...

Important step taken on the Canada Disability Benefit in Budget 2024, but funding falls short

More work must be done to lift Canadians with disabilities out of poverty TORONTO , April 17, 2024 /CNW/ - The federal government has taken an important step on the Canada Di...

Hydrinity Accelerated Skin Science Introduces MicroFusion Technology and Expands Facial Skincare Line with PRELUDE Facial Treatment Cleanser and HYDRI-C Vitamin C Moisturizer

The Next Generation Technology with the Power to Transform Skin MONROE, La. , April 15, 2024 /PRNewswire/ -- Hydrinity Accelerated Skin Science announced today the launch of t...